Nuvectis Pharma, Inc.

NVCT

Explore Our Financial Data > Companies > Nuvectis Pharma, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	NVCT
CIK	0001875558
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
Website	nuvectis.com
Phone	360-837-7232
CEO	Ronald E. Bentsur
Employees	8

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-20.16 million
Net Income	$-20.16 million
Net Income to Common	$-20.16 million
EPS	$-1.13

View All

Balance Sheet

Cash	$29.86 million
Assets	$30.15 million
Liabilities	$9.19 million
Common Equity	$20.95 million
Liabilities & Equity	$30.15 million

View All

Cash Flow Statement

Net Income	$-20.16 million
Cash From Operating Activities	$-12.06 million
Cash From Investing Activities	N/A
Cash From Financing Activities	$22.46 million
Change in Cash	$10.40 million

View All

Calculations

NOPAT	$-14.71 million
EBITDA	$-21.02 million
Price to Earnings	N/A
Price to Book	$9.98
ROE	-115.28%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event3rd Annual H.C. Wainwright BioConnect Inves

Article Link

Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 108.8% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Article Link

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Article Link

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategyCompleted $15.5M financing, extending projected cash runway into 1Q2027 FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or th

Article Link

Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025

We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Nuvectis Pharma Inc (NASDAQ:NVCT) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a […]

Article Link